Home/Filings/4/0001415889-24-002873
4//SEC Filing

Coen Stacy Ann 4

Accession 0001415889-24-002873

CIK 0000855654other

Filed

Feb 5, 7:00 PM ET

Accepted

Feb 6, 9:47 PM ET

Size

8.9 KB

Accession

0001415889-24-002873

Insider Transaction Report

Form 4
Period: 2024-02-02
Coen Stacy Ann
Chief Business Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-02-02+14,35077,857 total
  • Sale

    Common Stock

    2024-02-05$29.30/sh4,583$134,28273,274 total
  • Exercise/Conversion

    Restricted Stock Unit

    2024-02-0214,35028,700 total
    Exercise: $0.00Common Stock (14,350 underlying)
Footnotes (3)
  • [F1]Effected pursuant to a trading plan adopted on June 15, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  • [F2]Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  • [F3]The RSUs were awarded on 2/3/2023 and vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.

Issuer

ImmunoGen, Inc.

CIK 0000855654

Entity typeother

Related Parties

1
  • filerCIK 0001814150

Filing Metadata

Form type
4
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 9:47 PM ET
Size
8.9 KB